United States set
language
Menu Shopping cart $0 Search
Manufactured by BioVendor

sICAM-3 Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Other names:Intercellular adhesion molecule 3, CD50 antigen
  • Species:Human
Cat. No. Size Price


RAF105R 96 wells (1 kit) $721,83
PubMed Product Details
Technical Data

Type

Sandwich ELISA, HRP-labelled antibody

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Urine, Amniotic fluid, Cell culture supernatant

Sample Requirements

20 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.78–50 ng/ml

Limit of Detection

0.38 ng/ml

Intra-assay (Within-Run)

CV = 2.5%

Inter-assay (Run-to-Run)

CV = 2.0%

Spiking Recovery

106,00%

Dilution Linearity

96,00%

Summary

Research topic

Cell adhesion proteins

Summary

Intercellular Adhesion Molecule-3 (ICAM-3) is a member of the immunoglobulin supergene family and functions as a ligand for the Lymphocyte Function-Associated Antigen-1 (LFA-1). Three counter-receptors have been described for LFA-1, intercellular adhesion molecule 1 (ICAM-1), ICAM-2 and ICAM-3. LFA-1, an alpha-beta complex, is a member of the leukocyte integrin family which mediate lymphocyte adhesion.
ICAM-3 is a heavily glycosylated protein of 124 kDa with a polypeptide core of 57 kDa. The integral membrane protein with five immunoglobulin-like domains shares high homology to ICAM-1 and ICAM-2 in the extracellular region. In contrast to ICAM-1 and ICAM-2, ICAM-3 is absent on endothelia. ICAM-3 is expressed on resting lymphocytes, monocytes and neutrophils, representing the major LFA-1 ligand on these cells. The finding that adhesion of resting T lymphocytes to LFA-1 occurs primarily via ICAM-3 combined with the fact that ICAM-3 is much better expressed than other LFA-1 ligands on monocytes and resting lymphocytes implies an important role for ICAM-3 in the initiation of immune responses. ICAM-3 was found to be involved in the regulation of LFA-1/
ICAM-1 dependent leukocyte intercellular interactions. The initial interaction of ICAM-3 with LFA-1 might increase LFA-1-mediated cell binding to ICAM-1. Furthermore, ICAM-3 expression has been shown for dendritic epidermal Langerhans cells, whereas it is absent on other dendritic cells from different lymphoid organs. Thus potential function of ICAM-3 at the initiation phase of LC-leukocyte interactions taking place during skin
localized immune reactions can be postulated. Recent data suggest that ICAM-3 expression can be induced on endothelial cells in lymphoid neoplasms as shown for Hodgkin's and non-Hodgkin's disease. ICAM-3 is a very interesting molecule involved in the initial immune response thus suggesting an important role as a disease marker for a number of different indications and pathological situations.

Related Products Docs